Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s disease are characterized by the progressive loss of neurons.
Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s disease are characterized by the progressive loss of neurons. The resulting debilitating symptoms, such as loss of memory and cognition, and motor impairment, can significantly degrade patients’ quality of life, confining them to round-the-clock care. While currently used drugs help alleviate symptoms, curative treatments are lacking, thus underscoring the need for novel therapeutic strategies. One such strategy involves the induction of neuronal differentiation, which can replenish lost neurons and potentially stall or reverse neurodegeneration.
Vitamin K, a fat-soluble vitamin with established roles in blood coagulation and bone metabolism, has been recently implicated in neuronal differentiation and neuroprotection. However, the therapeutic activity of naturally active vitamin K compounds like menaquinone 4 (MK-4) may be insufficient for their application in regenerative medicine against neurodegenerative diseases.
In a new pioneering study published online in the journalACS Chemical Neuroscienceon July 03, 2025, a team of researchers led by Associate Professor Yoshihisa Hirota and Professor Yoshitomo Suhara from the Department of Bioscience and Engineering, Shibaura Institute of Technology, Japan, has designed and synthesized novel vitamin K analogues with enhanced neuroactive properties. Also, they report a unique mechanism of action by which vitamin K induces neuronal differentiation.
Read More: Shibaura Institute of Technology
Photo Credit: DeltaWorks via Pixabay
